FDA Inspection 1310410 — Labcorp Drug Development
The FDA completed an inspection of Labcorp Drug Development on January 30, 2026 in Shanghai. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- January 30, 2026
- Fiscal Year
- 2026
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Shanghai (China)
Additional Details
Bioanalytical BA/BE